MCT’s collaboration with Onxeo on HCC Phase III study in Middle East

/ News /

Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag

Related Posts

New Head of Clinical Operation join MCT

News /

Rita Zeidan Aji joined MCT on 01/03/13 as Head of Clinical Operation. Rita has more than 8 years experience in clinical research through her previous…